SRRK Stock Forecast & Price Target

Scholar Rock Holding Corp’s stock is viewed favorably due to its recent price increase of approximately 4%, suggesting positive market sentiment following significant developments. The company is considered undervalued, trading at around 14 times net cash, which indicates a compelling risk/reward profile over the next 12 to 24 months. Furthermore, positive results from the Phase 3 SAPPHIRE trial bolster expectations for regulatory approval and commercial application, with potential for label expansion, although management has acknowledged the possibility of delays.

Scholar Rock Holding Corp faces significant challenges that contribute to a negative outlook on its stock. The delay in the commercial launch of apitegromab, now pushed back to 2026 in the US and 2026 in the EU, has resulted in a revised projection of peak sales down to $1.7 billion by 2035, raising concerns regarding competitive risks and potential market share losses. Additionally, the issuance of a Complete Response Letter (CRL) underscores increased regulatory hurdles and necessitates a resubmission of the Biologics License Application (BLA), further complicating the company's path to realizing its commercial potential.